Trial · NCT06551844
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Viral clearance rate | From randomization until day 5 of study | Rate of viral clearance estimated under a hierarchical log-linear model fit to the serial viral load measurements over 5 days after enrolment. The viremia kinetics will be measured using the qRT-PCR assay, which will be performed on samples taken twice a day from day 1 to day 3 of study and then once a day on days 4 and 5 of study (total 9 samples per patient). |
| Primary | Number of AEs (grade 3, 4 and 5) | Until day 30 post-enrolment | All patients will be followed up daily until discharge and then at around days 30 after randomization to collect information on clinical progress of dengue illness and any adverse events occurring during the study course. All AEs and SAEs will be recorded. |
| Secondary | Area under the viremia curve | From randomisation until day 5 of study | Area under the curve (AUC) of the serial viremia measurements during the first 5 days of study |
| Secondary | Viral log reduction | up to 48 hours of study | Reduction of viremia at the 24 and 48 hours compared to baseline |
| Secondary | NS1 clearance time | up to day 5 | Time to NS1 clearance as estimated under a non-linear model |
| Secondary | Number of patients progress to severe dengue (WHO 2009 criteria) | From enrolment until discharge, assessed up to 30 days | All patients will be followed up daily until discharge to collect information about the clinical progress of dengue |
| Secondary | Number of patients requiring for ICU admission | From enrolment until discharge, assessed up to 30 days | All patients will be followed up daily until discharge to collect information about the clinical progress of dengue |
| Secondary | Fever clearance time | From enrolment until discharge, assessed up to 30 days | Time elapsed from enrolment to the afebrile time-point (defined as body temperature \<37.5 °C for at least 48 hours) |
| Secondary | Platelet nadir | Until day 30 post-enrolment | The lowest platelet count recorded during admission |
| Secondary | Maximum AST/ALT | Until day 30 post-enrolment | The highest values of AST/ALT measured |
| Secondary | Change in haematocrit | Until day 30 post-enrolment | Change in haematocrit during the hospitalisation |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06551844/registered